$BVAXF Results Drive New Attention to Breast Cancer Play
12-17-25
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.
Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II to III breast cancer.
The Phase 1 study evaluated MVP S in combination with letrozole, a commonly prescribed neoadjuvant hormone therapy, in postmenopausal patients prior to surgery. According to the company, the combination generated a strong immune response and meaningful biological activity across all treated participants. While the study enrolled only three patients, the consistency of the results is worth noting.
All three patients experienced at least a 50 percent reduction in Ki 67, a key biomarker used to measure tumor cell proliferation. Median Ki 67 levels declined from 24 percent at biopsy to 6 percent at surgery following treatment. One patient also demonstrated an eight fold increase in survivin specific interferon gamma T cells, a signal associated with enhanced immune mediated tumor response.
MVP S is built on BioVaxys proprietary DPX immune educating platform, which differs from traditional vaccine approaches by avoiding immediate antigen release at the injection site. Instead, the platform forces active uptake by immune cells and delivery to lymph nodes, promoting a sustained and targeted immune response. The therapy targets survivin, a cancer antigen commonly overexpressed in breast cancer and other solid tumors, and often associated with resistance to aromatase inhibitors such as letrozole.
The results address a well recognized challenge in hormone receptor positive, HER2 negative breast cancer. While neoadjuvant hormone therapy can reduce the need for chemotherapy and allow breast conserving surgery in roughly half of patients, responses vary widely and complete responses remain uncommon. HR positive, HER2 negative tumors represent the largest segment of the breast cancer market, accounting for more than half of total cases, with the broader HER2 negative market projected to exceed $21 billion by the end of the decade.
Management described the data as encouraging and indicated plans to further analyze systemic immune responses and tumor samples collected before and after treatment. That additional profiling is expected to support the design of a Phase 2 study aimed at modifying the tumor immune environment in higher risk patients.
While still early, the study reinforces the broader potential of BioVaxys platform across multiple oncology indications. MVP S is already being evaluated in later stage studies for other cancers, positioning this breast cancer data as an incremental validation of the company’s approach.
12-17-25
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.
Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II to III breast cancer.
The Phase 1 study evaluated MVP S in combination with letrozole, a commonly prescribed neoadjuvant hormone therapy, in postmenopausal patients prior to surgery. According to the company, the combination generated a strong immune response and meaningful biological activity across all treated participants. While the study enrolled only three patients, the consistency of the results is worth noting.
All three patients experienced at least a 50 percent reduction in Ki 67, a key biomarker used to measure tumor cell proliferation. Median Ki 67 levels declined from 24 percent at biopsy to 6 percent at surgery following treatment. One patient also demonstrated an eight fold increase in survivin specific interferon gamma T cells, a signal associated with enhanced immune mediated tumor response.
MVP S is built on BioVaxys proprietary DPX immune educating platform, which differs from traditional vaccine approaches by avoiding immediate antigen release at the injection site. Instead, the platform forces active uptake by immune cells and delivery to lymph nodes, promoting a sustained and targeted immune response. The therapy targets survivin, a cancer antigen commonly overexpressed in breast cancer and other solid tumors, and often associated with resistance to aromatase inhibitors such as letrozole.
The results address a well recognized challenge in hormone receptor positive, HER2 negative breast cancer. While neoadjuvant hormone therapy can reduce the need for chemotherapy and allow breast conserving surgery in roughly half of patients, responses vary widely and complete responses remain uncommon. HR positive, HER2 negative tumors represent the largest segment of the breast cancer market, accounting for more than half of total cases, with the broader HER2 negative market projected to exceed $21 billion by the end of the decade.
Management described the data as encouraging and indicated plans to further analyze systemic immune responses and tumor samples collected before and after treatment. That additional profiling is expected to support the design of a Phase 2 study aimed at modifying the tumor immune environment in higher risk patients.
While still early, the study reinforces the broader potential of BioVaxys platform across multiple oncology indications. MVP S is already being evaluated in later stage studies for other cancers, positioning this breast cancer data as an incremental validation of the company’s approach.
